You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 286 No. 5, August 1, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Atorvastatin for Acute Coronary Syndromes

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study reported by Dr Schwartz and colleagues1 show that data on statins in acute coronary syndromes (ACS) need careful interpretation. Results of the MIRACL study showed no benefit on clinical end points (ie, death, nonfatal myocardial infarction, and cardiac arrest) but did show a reduction in symptomatic ischemic episodes requiring hospitalization. These results likely overstate the benefits of statin therapy, as patients who underwent percutaneous coronary intervention (PCI) during the trial period were excluded from the primary combined end point.

Coronary revascularization can be performed for symptomatic relief as has been demonstrated in many trials, including the Atorvastatin versus Revascularization Treatment (AVERT) study.2 Results of the AVERT study showed a significant benefit of angioplasty in the reduction of symptoms of angina in patients who were treated with atorvastatin, 80 mg/d. Thus, to relegate the need . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial
Gregory G. Schwartz, Anders G. Olsson, Michael D. Ezekowitz, Peter Ganz, Michael F. Oliver, David Waters, Andreas Zeiher, Bernard R. Chaitman, Sally Leslie, Theresa Stern, and for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators
JAMA. 2001;285(13):1711-1718.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.